pharmacokinetics of glp-1 receptor agonists Evaluation the of agonist delivered through the BioJet™ oral biotherapeutic delivery platform in a porcine model: an update GLP-1-based therapies for type 2
Description
Physicians on Sermo share experiences with GLP-1 weight loss drugs and risks
The rise of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has revolutionized weight loss treatmentsbut how do they impact the absorption of other medications
Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant
Discover Ozempic alternatives for type 2 diabetes and weight loss, including GLP-1s and oral medications
A new short-term CMS demonstration changes that for 18 months.
